FY2025 Earnings Estimate for TNYA Issued By Lifesci Capital

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Investment analysts at Lifesci Capital dropped their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in a research report issued to clients and investors on Tuesday, December 16th. Lifesci Capital analyst C. Jubinville now anticipates that the company will post earnings per share of ($0.75) for the year, down from their previous forecast of ($0.74). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q4 2025 earnings at ($0.17) EPS.

Several other research firms have also weighed in on TNYA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, October 8th. Canaccord Genuity Group decreased their target price on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Chardan Capital lowered their price target on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Friday, December 12th. Finally, HC Wainwright decreased their price objective on Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.25.

Tenaya Therapeutics Price Performance

Shares of NASDAQ:TNYA opened at $0.70 on Thursday. The company has a market capitalization of $116.64 million, a price-to-earnings ratio of -0.90 and a beta of 3.13. The firm’s 50 day simple moving average is $1.38 and its 200 day simple moving average is $1.12. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of large investors have recently bought and sold shares of TNYA. Scientech Research LLC bought a new position in shares of Tenaya Therapeutics during the 3rd quarter worth approximately $27,000. Mirador Capital Partners LP increased its stake in Tenaya Therapeutics by 38.2% in the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock valued at $38,000 after buying an additional 6,500 shares during the last quarter. DAFNA Capital Management LLC acquired a new stake in Tenaya Therapeutics in the 1st quarter valued at $27,000. Jefferies Financial Group Inc. acquired a new position in shares of Tenaya Therapeutics during the 3rd quarter worth about $99,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Tenaya Therapeutics in the 3rd quarter valued at about $117,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.